Samuel J. Holzmayer

Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

Jenny N. H. G. Ho, Dominik Schmidt, Theresa Lowinus et al. · Blood · 2022 · 55 citations · Full text

Life Sciences, Immunology, Oncology +12

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato et al. · Nature Communications · 2023 · 35 citations · Full text

Life Sciences, Immunology, Pharmacology +17

The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas

Samuel J. Holzmayer, Kai Liebel, Ilona Hagelstein et al. · Frontiers in Immunology · 2024 · 14 citations · Full text

Life Sciences, Immunology, Oncology +17

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody

Sylwia A. Stefańczyk, Ilona Hagelstein, Martina S. Lutz et al. · Blood Cancer Journal · 2024 · 12 citations · Full text

Life Sciences, Immunology, Oncology +17

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer

Ramona Rudalska, Jule Harbig, Michael Förster et al. · Nature Cancer · 2025 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17